A federal jury in California has ruled in favor of drugmaker Merck in a high-stakes lawsuit against rival Gilead Sciences concerning patents for lucrative new drugs for hepatitis C. Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead's sofosbuvir infringes on those patents. Sofosbuvir is the active ingredient in Gilead's Sovaldi and a component of its Harvoni, which together brought in $19.1 billion last year.